tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

CING Stock Latest News

Cingulate announces efficacy results from Phase 3 study of CTx-1301
The FlyCingulate announces efficacy results from Phase 3 study of CTx-1301
17d ago
CING
Cingulate price target lowered to $11 from $12 at Roth Capital
PremiumThe Fly
Cingulate price target lowered to $11 from $12 at Roth Capital
19d ago
CING
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion
PremiumCompany Announcements
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion
22d ago
CING
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301
PremiumThe Fly
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301
23d ago
CING
Cingulate Inc Terminates Grant Agreement with Foundation
PremiumCompany Announcements
Cingulate Inc Terminates Grant Agreement with Foundation
24d ago
8K
CING
Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301
PremiumRatingsCingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301
1M ago
CING
Cingulate announces results from high-dose fed/fast study of CTx-1301
Premium
The Fly
Cingulate announces results from high-dose fed/fast study of CTx-1301
1M ago
CING
Cingulate Inc Secures $3M Grant for Anxiety Drug
Premium
Company Announcements
Cingulate Inc Secures $3M Grant for Anxiety Drug
2M ago
8K
CING
Cingulate receives $3M grant from to accelerate development of CTx-2103
PremiumThe Fly
Cingulate receives $3M grant from to accelerate development of CTx-2103
2M ago
CING
Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating
PremiumRatings
Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating
2M ago
CING
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301
PremiumThe Fly
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301
2M ago
CING
Cingulate Inc. Reports 2024 Financial and Development Milestones
PremiumCompany Announcements
Cingulate Inc. Reports 2024 Financial and Development Milestones
2M ago
CING
Cingulate sees cash runway sufficient into Q4
PremiumThe FlyCingulate sees cash runway sufficient into Q4
2M ago
CING
Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301
Premium
Ratings
Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301
3M ago
CING
Cingulate, Inc. (CING) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Cingulate, Inc. (CING) Q4 Earnings Cheat Sheet
3M ago
CING
Cingulate Inc. Advances Towards FDA Approval for CTx-1301
PremiumCompany Announcements
Cingulate Inc. Advances Towards FDA Approval for CTx-1301
3M ago
8K
CING
Cingulate reports safety results from final Phase 3 trials for CTx-1301
PremiumThe Fly
Cingulate reports safety results from final Phase 3 trials for CTx-1301
3M ago
CING
Cingulate price target adjusted to $20 from $8 at H.C. Wainwright
PremiumThe Fly
Cingulate price target adjusted to $20 from $8 at H.C. Wainwright
4M ago
CING
Cingulate initiated with a Buy at Roth MKM
PremiumThe Fly
Cingulate initiated with a Buy at Roth MKM
5M ago
CING
Cingulate Inc Completes Key FDA Study for ADHD Drug
PremiumCompany AnnouncementsCingulate Inc Completes Key FDA Study for ADHD Drug
5M ago
8K
CING
Cingulate completed final FDA-required study for CTx-1301 for ADHD
Premium
The Fly
Cingulate completed final FDA-required study for CTx-1301 for ADHD
5M ago
CING
Cingulate Inc Secures $5M Financing for Strategic Growth
Premium
Company Announcements
Cingulate Inc Secures $5M Financing for Strategic Growth
6M ago
8K
CING

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >